XML 88 R13.htm IDEA: XBRL DOCUMENT
v2.4.0.6

Financial Instruments | 12 Months Ended
--- | ---
Dec. 31, 2012
Financial Instruments [Abstract] |
FINANCIAL INSTRUMENTS | NOTE 5: FINANCIAL INSTRUMENTS Cash, Cash Equivalents and Marketable Securities The following tables show our cash and available-for-sale securities’ amortized cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category recorded as cash and cash equivalents or short and long-term marketable securities as of December 31, 2012 and December 31, 2011 (in thousands):
|  | December 31, 2012 |
|  | Amortized Cost |  |  | Unrealized Gains |  |  | Unrealized Losses |  |  | Fair Value |  |  | Cash and Cash Equivalents |  |  | Short-Term Marketable Securities |  |  | Long-Term Marketable Securities |
Cash |  | $ | 141,460 |  |  | $ | — |  |  | $ | — |  |  | $ | 141,460 |  |  | $ | 141,460 |  |  | $ | — |  |  | $ | — |
Level 1: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Money market funds |  |  | 215,052 |  |  |  | — |  |  |  | — |  |  |  | 215,052 |  |  |  | 215,052 |  |  |  | — |  |  |  | — |
Subtotal |  |  | 356,512 |  |  |  | — |  |  |  | — |  |  |  | 356,512 |  |  |  | 356,512 |  |  |  | — |  |  |  | — |
Level 2: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. agency securities |  |  | 13,634 |  |  |  | 4 |  |  |  | (3 | ) |  |  | 13,635 |  |  |  | — |  |  |  | 7,635 |  |  |  | 6,000 |
Commercial paper |  |  | 48,710 |  |  |  | 15 |  |  |  | (22 | ) |  |  | 48,703 |  |  |  | 9,999 |  |  |  | 38,704 |  |  |  | — |
Corporate securities |  |  | 162,050 |  |  |  | 12 |  |  |  | (180 | ) |  |  | 161,882 |  |  |  | 1,004 |  |  |  | 67,630 |  |  |  | 93,248 |
Municipal securities |  |  | 5,003 |  |  |  | — |  |  |  | (2 | ) |  |  | 5,001 |  |  |  | — |  |  |  | 5,001 |  |  |  | — |
Subtotal |  |  | 229,397 |  |  |  | 31 |  |  |  | (207 | ) |  |  | 229,221 |  |  |  | 11,003 |  |  |  | 118,970 |  |  |  | 99,248 |
Total |  | $ | 585,909 |  |  | $ | 31 |  |  | $ | (207 | ) |  | $ | 585,733 |  |  | $ | 367,515 |  |  | $ | 118,970 |  |  | $ | 99,248 |
|  | December 31, 2011 |
|  | Amortized Cost |  |  | Unrealized Gains |  |  | Unrealized Losses |  |  | Fair Value |  |  | Cash and Cash Equivalents |  |  | Short-Term Marketable Securities |  |  | Long-Term Marketable Securities |
Cash |  | $ | 114,532 |  |  | $ | — |  |  | $ | — |  |  | $ | 114,532 |  |  | $ | 114,532 |  |  | $ | — |  |  | $ | — |
Level 1: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Money market funds |  |  | 69,000 |  |  |  | — |  |  |  | — |  |  |  | 69,000 |  |  |  | 69,000 |  |  |  | — |  |  |  | — |
Total |  | $ | 183,532 |  |  | $ | — |  |  | $ | — |  |  | $ | 183,532 |  |  | $ | 183,532 |  |  | $ | — |  |  | $ | — |
Our cash and cash equivalents consist of cash on hand in global financial institutions, money market funds and marketable securities, with maturities of 90 days or less at the date purchased. The remaining maturities of our long-term marketable securities range from one to three years and our short-term marketable securities include maturities that were greater than 90 days at the date purchased and have 12 months or less remaining at December 31, 2012. We classify our cash equivalents and marketable securities within Level 1 and Level 2 as we value our cash equivalents and marketable securities using quoted market prices (Level 1) or alternative pricing sources (Level 2). The valuation technique we used to measure the fair value of money market funds were derived from quoted prices in active markets for identical assets or liabilities. Fair values for our U.S. agency securities, commercial paper, corporate securities and municipal securities and corporate notes are considered “Level 2” valuations because they are obtained from pricing sources for identical or comparable instruments, rather than direct observations of quoted prices in active markets. There were no sales of our marketable securities for the years ending December 31, 2012, 2011 and 2010. As of December 31, 2012, we have marketable securities with a total fair value of $200.0 million in a total gross unrealized loss position of $0.2 million. We consider the declines in market value of our marketable securities investment portfolio to be temporary in nature and do not consider any of our investments other-than-temporarily impaired. When evaluating an investment for other-than-temporary impairment, we review factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, and the our intent to sell, or whether it is more likely than not we will be required to sell the investment before recovery of the investment’s cost basis. During the years ended December 31, 2012, 2011 and 2010, we did not recognize any impairment charges. We did not have any investments in marketable securities that were in a continuous unrealized loss position for 12 months or greater at December 31, 2012 or 2011. Derivative Financial Instruments In the normal course of business, we are exposed to the impact of foreign currency fluctuations, which we attempt to mitigate through the use of derivative instruments. Accordingly, we have entered into forward contracts to reduce the effects of fluctuating foreign currency exchange rates on our cash flows denominated in foreign currencies. We do not use derivatives for trading or speculative purposes. In accordance with current accounting guidance on derivative instruments and hedging activities, we record all our derivative instruments as either an asset or liability measured at their fair value. Our derivative instruments are typically short-term in nature. Our current forward contracts are not designated as hedges. Consequently, any gain or loss resulting from the change in fair value is recognized in the current period earnings. These gains or losses are offset by the exposure related to receivables and payables with our foreign subsidiaries. We recorded a net realized and unrealized loss in Other, net of $0.7 million for the year ended December 31, 2012 related to our forward contracts in our consolidated and combined statement of operations. The net cash received or paid related to our derivative instruments are classified as operating in our consolidated and combined statements of cash flows, which is based on the objective of the derivative instruments. No derivative instruments were entered into or settled during the years ended December 31, 2011 and 2010. The following table shows the fair value and notional principal amounts of our outstanding or unsettled derivative instruments that are not designated as hedging instruments:
|  |  |  |  | December 31, 2012 |
|  | Balance Sheet Caption |  |  | Fair Value of Derivative (2) |  |  |  |  |  | U.S. Dollar Notional |
($ in thousands) |  |  |  |  | Asset |  |  | Liability |  |  |  |
Foreign exchange-forward contracts (current) |  |  | Accrued and other current liabilities | (1) |  | $ | — |  |  | $ | $64 |  |  | $ | 2,710 |
(1) | Current derivative contracts address foreign exchange fluctuations for the Euro versus the U.S. Dollar.
(2) | The fair value of our derivative liability is measured using Level 2 fair value inputs, as we use a pricing model that takes into account the contract terms as well as current foreign currency exchange rates in active markets.
Concentration of Credit Risk Counterparties to currency exchange derivatives consist of major international financial institutions. We monitor our positions and the credit ratings of the counterparties involved and, by policy limits, the amount of credit exposure to any one party. While we may be exposed to potential losses due to the credit risk of non-performance by these counterparties, losses are not anticipated. Other Financial Instruments Other financial instruments not measured at fair value on a recurring basis include trade receivables, related party receivables, trade payables, short-term debt, accrued and other current liabilities and long-term debt. With the exception of long-term debt, the carrying amount approximates fair value because of the short maturity of these instruments as reported on the consolidated balance sheets as of December 31, 2012 and December 31, 2011. The carrying value of the long-term borrowings outstanding on our Credit Agreement bear interest at a variable rate and therefore is also considered to approximate fair value. In addition during 2012 we had a redeemable noncontrolling interest which was considered a Level 3 liability. The total liability balance at December 31, 2012 and December 31, 2011 is $0 and $3.9 million respectively, and is included in redeemable noncontrolling interests in the mezzanine section of the consolidated balance sheets. Refer to “Note 14—Redeemable Noncontrolling Interest’ below for additional information. We did not have any Level 3 assets for the periods ended December 31, 2012 or 2011.

X
- Details
Name: | trip_FinancialInstrumentsAbstract
Namespace Prefix: | trip_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures. + References No definition available. + Details
Name: | us-gaap_FinancialInstrumentsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration